Genkyotex Company
Genkyotex is a biopharmaceutical company that develops innovative drugs to treat acute and chronic diseases by blocking enzymes that produce oxygen radicals. They aim to improve specificity, safety, and efficacy over existing antioxidant therapies and target therapeutic areas such as cardiovascular, metabolic, and neurodegenerative diseases. Genkyotex is the leading company in developing NOX therapies by selectively inhibiting NOX enzymes that amplify multiple disease processes like fibrosis, inflammation, pain processing, cancer development, and neurodegeneration.
Investors
Connections
Headquarters:
Geneva, Geneve
Employee Number:
11-50
Estimated Revenue:
€1.6 million
Founded Date:
2006
Industry:
P4 Medicine